Abstract
In the last years, Poly(ADP-ribose)-polymerase 1 inhibitors (PARPi) became a standard treatment option for patients with recurrent platinum-sensitive ovarian cancer and recently have been approved for maintenance use in the first-line setting. Biomarker subgroup analysis consistently revealed higher benefit for patients with homologous recombination deficiency (HRD; BRCA1/2m and/or genomic instability (GIS) positive), demonstrating the value of biomarker testing in this setting. The Myriad MyChoice assay has been the most commonly used HRD assay applied in the majority of clinical studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
